跨国制药公司正在寻求将数千万美元的预付款转化为价值数十亿美元的治疗方案。这一次,中国创新药成为跨国企业争夺的目标。据Global Data的一项最新数据,今年至今,美国制药公司已经签署了14项与中国药品相关的许可协议,涉及肥胖症疗法、心脏病和癌症在研药物,潜在价值达到183亿美元。而去年同期仅达成了两项此类交易。到2030年前,由于大量重磅药品专利即将到期,将出现价值高达2000亿美元的药品失去...
Source Link跨国制药公司正在寻求将数千万美元的预付款转化为价值数十亿美元的治疗方案。这一次,中国创新药成为跨国企业争夺的目标。据Global Data的一项最新数据,今年至今,美国制药公司已经签署了14项与中国药品相关的许可协议,涉及肥胖症疗法、心脏病和癌症在研药物,潜在价值达到183亿美元。而去年同期仅达成了两项此类交易。到2030年前,由于大量重磅药品专利即将到期,将出现价值高达2000亿美元的药品失去...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.